Novo Nordisk A/S raised its forecasts for the second time this year on a rosy outlook for its obesity and diabetes drugs, though the firm’s US shares fell as sales of the new Wegovy weight-loss pill failed to top analysts’ expectations.
Source: [Bloomberg Markets](https://www.bloomberg.com/news/articles/2026-08-04/novo-nordisk-boosts-forecast-on-soaring-glp-1-sales)